Other specified neuromuscular junction or muscle diseases
Conditions
Interventions
Test group:Bromonium Bromide 8 µ g/kg and Neostigmine 40 µ g/kg
Control group:Atropine sulfate 16 µ g/kg and neostigmine 40 µ g/kg
Sponsors
The First Affiliated Hospital of Zhengzhou University, Department of Anesthesiology
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Elderly patients aged >=65 years requiring general anesthesia for surgery 2.Postoperatively receiving neostigmine to reverse the residual effects of non-depolarizing neuromuscular blockers 3.ASA physical status classification I/II 4.Body Mass Index (BMI) between 18.5 and 30 5.Voluntary participants who provide informed consent
Exclusion criteria
Exclusion criteria: 1.Allergy to anticholinergic drugs and their components 2.Abnormal liver or kidney function (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or total bilirubin (TBiL) >= 2 × ULN; serum creatinine (Cr) >= 2 × ULN, or participants requiring dialysis 3.Currently using medications that affect the cholinergic system 4.Presence of severe cardiovascular, respiratory, gastrointestinal diseases, or autonomic neuropathy 5.Considered unsuitable for participation in this trial by the investigator 6.Participated in other clinical studies of drugs or medical devices within the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| heart rate;Systemic Vascular Resistance Index, SVRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| cardiac output, CO;cardiac index, CI;cardiac cycle efficiency;dp/dt;SBP;DBP;MAP;SpO2;TVD;Pulse Pressure Variation, PPV;Perfusion vascular density, PVD;MFI;HI; | — |
Countries
China
Contacts
Public ContactHua Shao
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed